Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Glaucoma

ClinicalTrials.gov lists 2,106 trials for Glaucoma or a narrower condition beneath it. Alcon Research has the most among industry and government lead sponsors, with 135.

MeSH D005901 Eye Diseases C11
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 80 Phase 1/2 Phase 1/2 46 Phase 2 Phase 2 160 Phase 2/3 Phase 2/3 18 Phase 3 Phase 3 223 Phase 4 Phase 4 277 Not applicable Not applicable 755 Observational Observational 545 Phase 1 Phase 1 80 Phase 1/2 Phase 1/2 46 Phase 2 Phase 2 160 Phase 2/3 Phase 2/3 18 Phase 3 Phase 3 223 Phase 4 Phase 4 277 Not applicable Not applicable 755 Observational Observational 545

Trials per phase (log scale)

1 more section with rows

1,356 of the 2,106 trials are tagged with Glaucoma itself; the rest are tagged with a narrower condition beneath it.

Get the Glaucoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Glaucoma trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 126

1992: 3 trials (Phase 3 3) 1993: 3 trials (Not applicable 1, Phase 3 2) 1994: 2 trials (Observational 1, Phase 3 1) 1995: 2 trials (Observational 1, Not applicable 1) 1996: 2 trials (Observational 1, Phase 3 1) 1997: 6 trials (Observational 2, Not applicable 2, Phase 3 2) 1998: 2 trials (Not applicable 1, Phase 2 1) 1999: 7 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 1) 2000: 9 trials (Observational 4, Not applicable 1, Phase 3 3, Phase 1 1) 2001: 7 trials (Observational 1, Not applicable 1, Phase 3 5) 2002: 13 trials (Observational 4, Not applicable 1, Phase 4 5, Phase 3 1, Phase 2 2) 2003: 23 trials (Observational 5, Not applicable 2, Phase 4 6, Phase 3 7, Phase 2 3) 2004: 22 trials (Observational 8, Not applicable 4, Phase 4 5, Phase 3 4, Phase 2 1) 2005: 52 trials (Observational 10, Not applicable 12, Phase 4 14, Phase 3 14, Phase 2 2) 2006: 71 trials (Observational 22, Not applicable 13, Phase 4 15, Phase 3 11, Phase 2 6, Phase 1/2 2, Phase 1 2) 2007: 82 trials (Observational 23, Not applicable 12, Phase 4 21, Phase 3 11, Phase 2 10, Phase 1/2 1, Phase 1 4) 2008: 88 trials (Observational 29, Not applicable 13, Phase 4 19, Phase 3 9, Phase 2/3 4, Phase 2 8, Phase 1/2 3, Phase 1 3) 2009: 90 trials (Observational 21, Not applicable 13, Phase 4 26, Phase 3 8, Phase 2/3 3, Phase 2 13, Phase 1/2 4, Phase 1 2) 2010: 92 trials (Observational 19, Not applicable 24, Phase 4 18, Phase 3 14, Phase 2/3 2, Phase 2 9, Phase 1/2 4, Phase 1 2) 2011: 126 trials (Observational 32, Not applicable 37, Phase 4 21, Phase 3 16, Phase 2 14, Phase 1/2 2, Phase 1 4) 2012: 80 trials (Observational 20, Not applicable 25, Phase 4 14, Phase 3 7, Phase 2 7, Phase 1/2 4, Phase 1 3) 2013: 98 trials (Observational 29, Not applicable 28, Phase 4 19, Phase 3 6, Phase 2 9, Phase 1/2 2, Phase 1 5) 2014: 96 trials (Observational 21, Not applicable 32, Phase 4 8, Phase 3 11, Phase 2/3 1, Phase 2 14, Phase 1/2 4, Phase 1 5) 2015: 71 trials (Observational 16, Not applicable 27, Phase 4 6, Phase 3 9, Phase 2/3 1, Phase 2 7, Phase 1 5) 2016: 84 trials (Observational 23, Not applicable 31, Phase 4 7, Phase 3 10, Phase 2 6, Phase 1/2 2, Phase 1 5) 2017: 89 trials (Observational 26, Not applicable 41, Phase 4 6, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 4) 2018: 110 trials (Observational 26, Not applicable 58, Phase 4 4, Phase 3 11, Phase 2/3 1, Phase 2 3, Phase 1/2 2, Phase 1 5) 2019: 82 trials (Observational 25, Not applicable 28, Phase 4 8, Phase 3 10, Phase 2 3, Phase 1/2 3, Phase 1 5) 2020: 91 trials (Observational 22, Not applicable 50, Phase 4 8, Phase 3 4, Phase 2 4, Phase 1/2 1, Phase 1 2) 2021: 106 trials (Observational 26, Not applicable 52, Phase 4 7, Phase 3 9, Phase 2 8, Phase 1/2 1, Phase 1 3) 2022: 99 trials (Observational 26, Not applicable 55, Phase 4 3, Phase 3 6, Phase 2 3, Phase 1/2 2, Phase 1 4) 2023: 91 trials (Observational 19, Not applicable 55, Phase 4 5, Phase 3 2, Phase 2/3 2, Phase 2 4, Phase 1/2 2, Phase 1 2) 2024: 78 trials (Observational 25, Not applicable 29, Phase 4 7, Phase 3 5, Phase 2 5, Phase 1 7) 2025: 103 trials (Observational 31, Not applicable 48, Phase 4 7, Phase 3 5, Phase 2/3 1, Phase 2 6, Phase 1/2 3, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 95
2025 103
2024 78
2023 91
2022 99
2021 106
2020 91
2019 82
2018 110
2017 89

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 120 trials starting in 2026 and about 100 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 34 months from start to primary completion across 155 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 1,361 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Glaucoma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 80
Phase 1/2 46
Phase 2 160
Phase 2/3 18
Phase 3 223
Phase 4 277
Not applicable 755
Observational 545
Expanded access 2

How many Glaucoma trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 56
Recruiting 183
Enrolling by invitation 17
Active, not recruiting 60
Completed 1,243

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Glaucoma trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Alcon Research 135
Allergan 82
Glaukos Corporation 48
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 27
Aerie Pharmaceuticals 25

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Glaucoma? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Timolol hemihydrate 27
Bimatoprost 17
Brimonidine 15

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Apo-Latanoprost 91
travoprost 0.003% 45
Latanoprost 0.005% 19
Cataract surgery 17
Latanoprost 0.005% Ophthalmic Solution 16

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Glaucoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Death 40 17
Pneumonia 40 25
Corneal endothelial cell loss 34 4
Intraocular pressure increased 30 11
Hypotony 25 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Glaucoma? (899)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Number of macula optical coherence tomography scans needed to detect glaucoma progression. The British journal of ophthalmology 2025 Yes
Comparison of Bent Ab-Interno Needle Goniectomy and Goniotomy in Primary Congenital Glaucoma: A Randomized Controlled Trial. Ophthalmology. Glaucoma 2025 Yes
PreserFlo MicroShunt versus trabeculectomy: an updated meta-analysis and systematic review. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2025 Yes
Initial Results of the Paul Ahmed Comparison (PAC) Study in Refractory Childhood Glaucoma. American journal of ophthalmology 2025 Yes
Outcomes of Circumferential Versus Hemi-gonioscopy-Assisted Transluminal Trabeculotomy for Congenital Glaucoma. American journal of ophthalmology 2025 Yes

Showing 5 of 899 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages